EMA’s CHMP backed new medicines from Hansoh, Innovent and AstraZeneca, according to a data byte summary tied to the committee’s November meeting. The update highlights multiple originators from China among recommendations, underscoring ongoing momentum in oncology product review pathways. For biotech teams, the key takeaway is not just the approvals status but the continued pattern of CHMP support for new entrants in oncology—an indicator of the direction of committee scrutiny toward novel mechanisms and clinical packages. While details on indications and labels were not included in the provided item, the decision context signals that manufacturing readiness and clinical differentiation remain central themes for first-cycle CHMP deliberations.